Safety and pharmacokinetics of inhaled aloxistatin: A first-in-human phase 1 dose escalation trial.
AIMS Aloxistatin (E64d) is a membrane-permeable cysteine protease inhibitor prodrug that is converted by esterases to the active metabolite E64c (loxistatin). This first-in-human study evaluated the safety, tolerability and pharmacokinetics of single ascending doses of inhaled E64d in healthy volunteers. METHODS In t...